Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.

ABSTRACT:

Introduction

As the prevalence of type 2 diabetes mellitus (T2DM) is anticipated to continue to rise worldwide, so too are the treatment options also continuing to expand. Current guidelines recommend individualized treatment plans which allow for provider choice and diversity of pharmacotherapeutic regimens. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is rapidly expanding, with dulaglutide (Trulicity™) as a once-weekly agent recently approved.

Aims

This article examines the evidence currently available on the efficacy and safety of dulaglutide for use in T2DM.

Evidence review

Dulaglutide has been shown to have similar efficacy and safety to other newer GLP-1 RAs, and better glycemic control than placebo. It lowers glycated hemoglobin (A1c), fasting

SUBMITTER: Edwards KL 

PROVIDER: S-EPMC4295897 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature